Alternatives to PostEra

Isomorphic Labs uses AI drug discovery models to design novel molecules and predict how candidate drugs will perform.

Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease.

Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.

Atomwise APEX Protocol screens 10 billion compounds in under 30 seconds for small-molecule drug discovery

Generate Biomedicines uses generative biology to design AI protein therapeutics — antibodies, enzymes, and cytokines — and move them into

Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.

Physics-based molecular simulation with AI for drug discovery and materials design.

Benchling unifies ELN, LIMS, and AI agents for biotech R&D in one cloud platform.

Causal AI drug discovery pairing 20+ petabytes of cellular data with human genetics to find true disease targets

Xaira Therapeutics pairs causal AI perturbation models X-Cell and X-Design with agentic and robotic labs to find, design, and validate new

Recursion runs AI drug discovery as a lab-in-the-loop engine — automated cellular imaging at scale feeding generative chemistry and a clinical pipeline.

AI drug discovery engine pairing 2M weekly automated lab experiments with a 50+ PB proprietary dataset.

WhiteLab Genomics' ALFRED platform predicts and optimizes molecular constructs for gene and RNA therapies before synthesis

AI-CRISPR target discovery platform pairing AlgenCRISPR gene modulation with the AlgenBrain foundation model for causal immunology and

Lamin is a lineage-native open data platform and LaminDB library for traceable, multimodal biotech data — query, govern, and version

Project-based AI biopharma team that delivers decision-grade research, analysis, and computational design in 3–5 days.

AI-driven scientific diligence software for pharma BD, biotech and life science investors evaluating in-licensing, M&A and investment

AI enzyme design for pharma manufacturing and life science tools, validated in Pando's own ultra-high-throughput screening lab.

Nanograb designs peptide-LNP targeting systems with biophysics-informed AI so genetic medicines reach a chosen cell type instead of the liver.

AI and computational bionanotechnology R&D partnership that designs field-ready molecular diagnostics for emerging biological threats in days, not 12+ months.

Owkin's K Pro is an autonomous AI scientist agent for biopharma R&D, turning multimodal patient data into drug discovery and clinical trial

Recursion OS pairs automated wet labs with AI models for AI drug discovery at up to 2 million weekly experiments.

Evotec is a life-science partner running AI-assisted drug discovery and Just–Evotec Biologics manufacturing.

Silico is Goodfire's interpretability agent for understanding and debugging the internals of your AI models.

Oncology real-world evidence platform combining high-fidelity patient data with AI-assisted cancer research insights.

All-in-human AI foundation models for precision neurology — vBx-1.0 predicts brain activity and therapy response from a blood draw.

Renamed: Deep 6 AI was acquired by Tempus AI in March 2025 and its trial matching folded into Tempus.

FDA-cleared AI for cancer pathology: prostate, breast, GI and pan-cancer detection on H&E slides, plus Virchow foundation models for research.

Quibim turns MRI, CT and PET scans into regulatory-cleared quantitative imaging biomarkers for prostate, brain, liver, breast and lung.

Google's umbrella health initiative: consumer health info, research tools like AlphaFold, and clinical AI research.